Codexis, Inc.

CDXS Healthcare Biotechnology

Codexis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.4 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue fell 2.69%, EPS grew 18.8%, free cash flow grew 48.6% and total debt fell 14.1%, each against the same quarter a year earlier.

1.25 0.11 −8.09%
Market cap
$148.9M
P/E
0.0×
Fwd P/E
−6.6×
Dividend yield
—
F-score
4/9
Altman Z
−4.75
Beneish M
−3.57
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
4 3 3 4 3 3 2 4 2 3
P/S ratio
2.02 5.90 3.03 2.20 19.27 18.76 13.20 14.39 7.53 3.74
Altman Z-Score
(4.75) (3.02) (3.23) 0.01 13.32 13.59 10.21 17.98 (0.29) (3.62)
P/FCF ratio
0.00 0.00 0.00 101.52 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(11.56) (10.79) (10.64) (2.00) (0.22) 2.07 (1.16) (7.83) (18.69) (24.38)
Beneish M-Score
(3.57) (3.19) (4.02) (3.12) (1.91) (2.44) (1.64) (2.07) (2.86) (3.52)
P/Operating CF
7.07 (21.26) (19.26) 62.06 3,059.15 (868.52) (246.88) (1,210.87) 49.40 35.41
P/B ratio
2.81 5.23 2.45 2.11 12.28 7.62 8.57 15.48 15.35 9.57
Price to Tangible BV
2.96 5.43 2.53 2.16 12.53 7.77 8.84 16.43 17.68 11.53
EV/Sales
1.47 5.14 2.28 1.65 18.57 16.91 12.24 13.51 6.92 3.37
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(5.34) (6.17) (3.04) 20.29 (136.34) (70.91) (66.69) (58.10) (39.55) (88.43)
EV/FCF
(4.34) (5.69) (2.84) 76.16 (69.33) (57.76) (51.43) (48.57) (35.56) (60.78)
Quick Ratio
3.51 3.74 2.37 3.12 4.51 7.03 7.17 3.67 1.72 2.03
Current Ratio
3.82 4.18 2.61 3.32 4.85 7.38 7.42 3.77 1.81 2.20
Net Debt/EBITDA
1.11 0.87 1.13 3.09 4.41 6.63 8.28 5.22 1.39 4.57
Debt/Assets
27.14% 19.40% 0.00% 15.29% 17.68% 10.07% 16.74% 0.12% 1.42% 2.48%
Debt/Equity
0.79 0.43 0.00 0.26 0.27 0.13 0.24 0.00 0.03 0.05
Asset Turnover
0.47 0.42 0.36 0.56 0.45 0.37 0.60 0.91 1.12 1.22
Operating CF/Net income
0.44 0.76 0.69 (0.34) 0.67 0.69 1.05 1.30 0.38 0.22
Capex/Depreciation
(0.63) (0.62) (0.37) (0.81) (2.32) (0.82) (0.82) (2.41) (0.94) (0.19)
Interest Coverage
(8.67) (5.63) (5.55) 281.30 (49.45) (59.06) (9.75) (16.83) (156.26) (142.73)
ROE
(74.88%) (85.03%) (65.89%) (21.73%) (12.72%) (17.42%) (14.75%) (26.91%) (105.38%) (40.77%)
ROA
(29.63%) (45.72%) (39.41%) (13.52%) (9.09%) (12.95%) (10.45%) (16.37%) (51.52%) (21.32%)
ROIC
(218.36%) (167.23%) (202.78%) (31.79%) (15.66%) (35.88%) (19.95%) (209.91%) 0.00% (719.42%)
Return on Tangible Assets
(52.03%) (73.08%) (104.26%) (24.62%) (14.20%) (14.20%) (11.36%) (19.83%) (100.41%) (50.30%)
Average Days of Receivables
52.86 89.24 99.46 102.07 115.31 130.88 101.99 81.12 86.10 44.28
Research and Development Expense of Revenue
74.31% 77.96% 83.95% 57.80% 53.38% 63.98% 49.48% 49.47% 59.29% 45.52%
Selling, General and Administrative Expense of Revenue
66.88% 92.93% 75.92% 37.64% 47.08% 50.75% 46.02% 48.34% 57.99% 52.05%
Intangible Assets out of Total Assets
0.02 0.02 0.02 0.01 0.01 0.01 0.02 0.04 0.06 0.09
Share Based Compensation of Revenue
13.67% 22.05% 14.22% 10.48% 11.07% 11.19% 10.14% 13.02% 14.18% 11.62%
Graham Net Nets
0.00 0.05 0.20 0.19 0.04 0.10 0.08 0.05 0.04 0.06
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(31.90%) (18.87%) (35.58%) (10.92%) (1.09%) (1.83%) (1.34%) (1.32%) (6.13%) (4.44%)
Free Cash Flow Yield
(16.79%) (15.32%) (26.49%) 0.99% (1.39%) (1.56%) (1.80%) (1.93%) (2.58%) (1.48%)
Revenue per Share
0.81 0.81 1.03 2.12 1.62 1.16 1.21 1.16 1.08 1.20
Operating CF per Share
(0.22) (0.67) (0.77) 0.17 (0.22) (0.28) (0.22) (0.27) (0.19) (0.05)
Capex per Share
(0.05) (0.06) (0.05) (0.13) (0.21) (0.06) (0.07) (0.05) (0.02) (0.02)
Free Cash Flow per Share
(0.27) (0.73) (0.83) 0.05 (0.43) (0.34) (0.29) (0.32) (0.21) (0.07)
Cash per Share
0.90 1.01 0.96 1.75 1.82 2.54 1.61 1.02 0.68 0.47
Shareholders Equity per Share
0.58 0.91 1.27 2.22 2.55 2.87 1.87 1.08 0.53 0.47
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.58 0.91 1.27 2.22 2.55 2.87 1.87 1.08 0.53 0.47
Free Cash Flow
(23.84) (53.63) (56.30) 3.01 (28.06) (20.21) (16.29) (16.86) (9.74) (2.71)
Working Capital
71.50 75.12 57.64 113.83 128.52 159.44 98.82 50.09 20.09 14.86
Capital Expenditures
(4.47) (4.22) (3.67) (8.28) (13.79) (3.75) (3.73) (2.77) (0.98) (0.85)
Net Current Asset Value
(0.45) 16.69 43.52 57.30 79.90 132.88 70.65 45.22 15.96 10.68
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.06 0.07 0.05 0.06 0.13 0.05 0.05 0.05 0.02 0.02
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.54 0.48 0.64 0.45 0.28 0.47 0.73 0.24 0.37 2.11
Cash ROIC
(14.08%) (31.58%) (36.98%) 1.01% (8.62%) (5.89%) (7.35%) (15.41%) (17.23%) (6.90%)
Accounts Receivable Turnover
5.70 3.53 2.42 3.86 3.62 3.15 4.20 4.80 5.64 7.37
Accounts Payable Turnover
4.25 3.71 2.79 12.19 7.45 4.92 5.51 3.83 3.68 2.56
Inventory Turnover
5.16 7.26 5.43 23.85 20.91 20.59 32.57 15.53 15.40 10.74
Average Days of Payables
60.74 63.60 169.46 31.15 49.22 78.89 61.20 88.21 90.31 158.38
Days of Inventory on Hand
71.02 40.31 76.51 19.47 19.06 25.60 8.66 17.04 26.39 30.88
Average Receivables
12.35 16.81 28.94 35.93 28.93 21.95 16.30 12.63 8.86 6.63
Average Payables
2.20 4.39 4.60 3.12 2.98 2.80 2.84 3.30 3.89 3.82
Average Inventory
1.81 2.24 2.36 1.59 1.06 0.67 0.48 0.81 0.93 0.91
Average Assets
148.40 142.79 193.48 248.39 234.01 185.36 114.18 66.45 44.64 40.15
Average Common Equity
58.73 76.77 115.71 154.59 167.25 137.81 80.91 40.43 21.82 20.99

Fold the line items

Columns are period end dates